BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules?

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Bruton's tyrosine kinase (BTK) inhibitors have been used for over a decade to treat lymphoid malignancies.
• Resistance to BTK inhibitors is a significant clinical challenge, driven by various factors including specific mutations and adaptive signaling pathways.

Purpose of the Study:

• To explore the evolving landscape of BTK inhibitor resistance.
• To investigate the potential of BTK degraders as a novel therapeutic strategy for lymphoid malignancies.
• To determine if BTK degraders circumvent or modify established resistance mechanisms.

Main Methods:

• Review of clinical data and resistance mechanisms associated with BTK inhibitors.
• Analysis of the mechanistic differences between BTK inhibitors and BTK degraders.
• Hypothetical modeling of resistance patterns in response to BTK degraders.

Main Results:

• BTK inhibitor resistance is multifaceted, involving drug-specific mutations, bypass signaling, and disease adaptations.
• BTK degraders represent a distinct therapeutic modality with a different mechanism of action compared to BTK inhibitors.
• The emergence of BTK degraders necessitates a re-evaluation of resistance dynamics.

Conclusions:

• BTK degraders may offer a strategy to overcome certain resistance mechanisms seen with BTK inhibitors.
• Understanding the nuances of resistance to both BTK inhibitors and degraders is crucial for optimizing treatment outcomes in lymphoid malignancies.